Şunu aradınız:: antikoagulacija (Slovence - İngilizce)

terapevtska antikoagulacija
therapeutic anticoagulation

antikoagulacija pri odraslih bolnikih s hit tipa ii in tromboembolijo:
anticoagulation in adult patients with hit type ii and thromboembolic disease:

zdravljenje se mora nadaljevati vsaj 5 dni in dokler se ne vzpostavi primerna peroralna antikoagulacija (internacionalno normalizirano razmerje 2 do 3).
treatment should be continued for at least 5 days and until adequate oral anticoagulation is established (international normalised ratio 2 to 3).

antikoagulacija pri odraslih bolnikih, ki imajo s heparinom inducirano trombocitopenijo (hit) tipa ii in tromboembolijo, ki zahteva parenteralno antitrombotično zdravljenje.
anticoagulation in adult patients with heparin-induced thrombocytopenia (hit) type ii and thromboembolic disease mandating parenteral antithrombotic therapy.

v primeru resne hemolize po prekinitvi zdravljenja z zdravilom soliris razmislite o naslednjih postopkih/načinih zdravljenja: transfuzija krvi (koncentriranih eritrocitov) ali izmenjalna transfuzija, če je eritrocitov pnh >50 % vseh eritrocitov (izmerjeno s pretočno citometrijo); antikoagulacija; kortikosteroidi; ali ponovna uvedba zdravila soliris.
if serious haemolysis occurs after soliris discontinuation, consider the following procedures/treatments: blood transfusion (packed rbcs), or exchange transfusion if the pnh rbcs are >50% of the total rbcs by flow cytometry; anticoagulation; corticosteroids; or reinstitution of soliris.